TF2- Small Cell Lung Cancer Radio Immunotherapy

Inclusion Criteria: • Patients with histologic diagnosis of SCLC who are in partial response or who have failed at least two lines of standard radiation and/or chemotherapy. Outside formal contra-indication, patients must have received at least one prior platinum-based chemotherapy. or * Patients with histologic diagnosis of NSCLC (without activating mutation of EGFR gene) who have failed at least one line of chemotherapy (platinum in combination with a third generation drug or combination of 2 third generation drug +/-bevacizumab in case of predominance of non-squamous tumor) * Age ≥ 18 years * At least 4-weeks after the previous treatment and have recovered from previous radio- or chemotherapy * Women of child-bearing potential must have a negative pregnancy test. * Karnofsky performance status ≥ 60 or ECOG performance status 0-2Karnofsky * Minimum life expectancy of 3 months * Positive CEA on immunohistology or plasma CEA ≥ 10 ng/mL * At least one measurable lesion by CT * At least one abnormal focus by FDG-PET * Imaging studies must be performed within 1-4 weeks before PRAIT study to document extent of disease * Signed informed consent form. Exclusion Criteria: * Pregnant or lactating woman. Women of child-bearing potential will be asked to practice adequate means of birth control for a minimum of 12 months after treatment. * Male patient refusing effective contraception for a minimum of 12 months after treatment. * Brain metastases but patients with brain metastases controlled after treatment by Surgery or radiotherapy since more than 4 weeks are eligibles for the study. An treatment by associated corticotherapy is authorized for these patients. * Known HIV or hepatitis * Any serious active disease or comorbid medical condition (according to the investigator's decision and information provided in the IDB) * Severe disorders of hemostasis or anticoagulant treatment cure * Extensive irradiation to more than 25% of their red marrow * Bone marrow involvement to more than 25% * External radiation to specific organs or areas at the maximum tolerated level * EGFR gene mutation in tumor (only for NSCLC) * Febrile aplasia during a previous chemotherapy * Neutrophils \< 1.5 G/l * Platelets \< 100 G/l * Uncontrolled diabetes * Poor renal function (creatinine level \> 2.5 maximum normal level) * Poor hepatic function (total bilirubin level \> 30 mmol/l, transaminases \> 2.5 maximum normal level) * Treatment with any investigational drug within 30 days before planned PRAIT and during the study * Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma, * Presence of anti-antibody reactivity * Known hypersensitivity to murine antibodies or proteins * Adult patient unable to give informed consent because of intellectual impairment.